Report error Found 68 of ic50 data for polymerid = 1322
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 16nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 105nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 105nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 105nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3 [540-1115](Human)
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 105nMAssay Description:The biochemical activity of compounds was determined by incubation with PERK recombinant enzyme (cytoplasmic domain corresponding to residues 540-111...More data for this Ligand-Target Pair
